Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.

  title={Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.},
  author={Clarke E Atkins and William A. Brown and Julie R Coats and Mary Ann Crawford and Teresa C DeFrancesco and Joel Edwards and Philip R Fox and Bruce W Keene and Linda B. Lehmkuhl and M.W. Luethy and Kathryn M. Meurs and J Petrie and Frank S. Pipers and Steven L. Rosenthal and Jennifer A Sidley and J Straus},
  journal={Journal of the American Veterinary Medical Association},
  volume={221 5},
OBJECTIVE To determine the effect of long-term administration of enalapril on renal function in dogs with severe, compensated mitral regurgitation. DESIGN Randomized controlled trial. ANIMALS 139 dogs with mitral regurgitation but without overt signs of heart failure. PROCEDURE Dogs were randomly assigned to be treated with enalapril (0.5 mg/kg [0.23 mg/lb], PO, q 24 h) or placebo, and serum creatinine and urea nitrogen concentrations were measured at regular intervals for up to 26 months… 

Figures from this paper

Long-term tolerability of benazepril in dogs with congestive heart failure.

  • J. PouchelonJ. King G. Strehlau
  • Medicine, Biology
    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology
  • 2004

Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.

Dogs with heart failure receiving spironolactone in addition to conventional treatment are not at a higher risk for AEs, death caused by cardiac disease, renal disease, or both, hyperkalemia, or azotemia.

Effects of enalapril in cats with pressure overload-induced left ventricular hypertrophy

Prospective evaluation of renal function in dogs with chronic mitral valve disease

Looking at the prevalence of azotemia in CMVD dogs, data suggests a link between heart and kidney function (despite the authors didn’t excluded aged-related coexistence of organ damage) and no statistical evidence to support a difference in WRF parameters in dogs experiencing CHF and dogs not experiencing it is suggested.

Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.

It was concluded that tepoxalin did not alter renal function in healthy Beagle dogs receiving ACEI, and renal uptake and plasma clearance of 99mTc-DTPA were not significantly modified.

Losartan versus enalapril in dogs asymptomatic carriers of myxomatous degeneration of mitral valve

It is concluded that losartan acts similarly to enalapril in the initial treatment (first 56 days) of dogs with DMVM class Ib and II of the CHF.

Clinical evaluation of enalapril maleate and furosemide usage in dogs with degenerative myxomatous mitral valve, CHF functional class Ib

Analysis of results showed that monotherapy based on enalapril maleate showed better efficiency of symptoms control in patients with CHF functional class Ib.

Retrospective evaluation of a dose‐dependent effect of angiotensin‐converting enzyme inhibitors on long‐term outcome in dogs with cardiac disease

Once daily dose frequency might optimize the cardioprotective benefit of ACEIs in dogs with cardiac disease, and within the subgroup of dogs in CHF at the time of ACEI prescription, higher ACEI dose was associated with improved survival at 2 years.

Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.

After repeated PO administration of ramipril, there were no alterations in any of the PK and PD parameters in healthy or renal-impaired dogs, and no adjustment of the recommended PO dosage of Ramipril is needed in dogs with moderate renal impairment.

[Head-to-head comparison of clinical, biochemical and functional effects of fosinopril and enalapril in patients with systolic heart failure].

Fosinopril and enalapril have similar short-term effects on event-free survival, ejection fraction, functional capacity and quality of life in patients with heart failure and patients on fos inopril presented with longer survival without event and had lower creatinine and BUN at the end-of the follow-up.



Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.

The deterioration of renal function after converting-enzyme inhibition in heart failure is not a toxic or immunologic reaction to therapy but results from specific hemodynamic events that can be ameliorated by sodium repletion.

Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.

Use of enalapril in combination withstandard treatment (diuretics with or without digoxin) appears to be beneficial over an extended period, compared with standard treatment alone.

Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group.

  • D. Sisson
  • Medicine
    Journal of veterinary internal medicine
  • 1995
This study shows the beneficial hemodynamic and clinical effects of adding enalapril to conventional therapy for dogs with heart failure and significantly greater decreases in class of heart failure, pulmonary edema score, and mobility score relative to baseline.

Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group.

  • J. Woodfield
  • Medicine
    Journal of veterinary internal medicine
  • 1995
The clinical efficacy and safety of enalapril were evaluated in dogs with moderate or severe heart failure and five dogs had to be removed from the study as a result of azotemia.

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

The angiotensin-converting--enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  • Medicine
    The New England journal of medicine
  • 1987
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.

The effect of combined therapy with captopril, furosemide, and a sodium-restricted diet on serum electrolyte concentrations and renal function in normal dogs and dogs with congestive heart failure.

Six of 10 dogs with congestive heart failure had at least one serum potassium concentration above the reference range sometime during the 5 weeks of observation, although the changes in the mean serum potassium concentrations were not statistically significant.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.